Alexander A. Sapegin
Alexander A. Sapegin has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Ionas S. Simutis
Sokolov Northwestern District Research and Clinical Center, Federal Medico-Biological Agency of Russia; I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
7 shared publications - Larisa Borisovna Gaikovaya
Northwestern State Medical University named after I.I. Mechnikov; 41 Kirochnaya str., Saint Petersburg, 191015, Russian Federation
4 shared publications - Mark S. Danilov
Sokolov North-Western District Scientific Clinical Center
4 shared publications - Kristina S. Blitzine
North-Western State Medical University Named After I.I. Mechnikov
3 shared publications - Daria G. Eremich
Sokolov North-Western District Scientific Clinical Center
2 shared publications - Gennady A. Boyarinov
Lobachevsky State University; Privolzhsky Research Medical University
2 shared publications
Latest Publications
- 23 April 2026
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 2,p. 84-92
Comparative evaluation of the efficacy of semi-elemental and polymeric nutritional formulas in combination with serotonin for the correction of nutritional status disorders and gastrointestinal insufficiency in the postoperative period in oncological patients: results of a pilot study
Objective. To improve perioperative outcomes in patients with malignant GIT tumors and pre-existing NI through early use of a semi-elemental therapeutic formula in combination with continuous infusion of serotonin adipinate. Material and methods. This was a prospective, randomized, single-center pilot study including 44 patients aged >65 years after elective GIT surgery for malignant neoplasms with documented NI (≥2 points on NRS-2002) and GII (≥3 points on the LIFE scale). All patients received a low-rate intravenous infusion of serotonin adipinate (20 mg/day) until resolution of GII. Early enteral nutritional support was initiated simultaneously: in the main group, a semi-elemental whey protein hydrolysate-based formula (Peptamen Intense) was used; in the control group, a standard polymeric formula (Nutricomp Intensive) was administered. The severity of GII was assessed using the LIFE scale; plasma serotonin levels, amino acid profile (methionine, arginine, valine, citrulline, etc.), laboratory markers of nutritional status and their dynamics were evaluated on postoperative days 1, 2, and 5. Results. In both groups, serotonin supplementation led to a rapid normalization of initially reduced plasma serotonin levels (from 49.8 ng/mL [19; 71.2] to values within the reference range already by postoperative day 1, with subsequent stabilization). In the main group, the semi-elemental formula provided a more pronounced nutritional effect: by day 5 there was a significant restoration (p<0.05) of initially decreased methionine, arginine, and valine concentrations compared with the control group. A less pronounced catabolic trend was observed for citrulline, a marker of functional enterocyte mass, along with a more favorable course of GII according to the LIFE scale (p<0.05) in the main group. Significant negative correlations were identified between GII severity and arginine levels (r=–0.994; 95% CI [–0.9968; –0.9890], p=0.01) and citrulline levels (r=–0.614; 95% CI [–0.819; –0.271], p=0.04), indicating active utilization of these amino acids in reparative processes under combined therapy. Conclusion. The results of this pilot study demonstrate the potential of early use of a semi-elemental enteral formula on the background of prokinetic therapy with serotonin adipinate to optimize postoperative restoration of GIT function and correction of malnutrition in oncologic patients with pre-existing NI and GII. The data obtained indicate a more favorable dynamics of the amino acid profile (methionine, arginine, valine, citrulline) and a trend toward less severe GII on the LIFE scale compared with a standard polymeric formula. However, given the small sample size and short follow-up period, these findings require confirmation in larger multicenter studies.
- 23 April 2026
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 2,p. 84-92
Comparative evaluation of the efficacy of semi-elemental and polymeric nutritional formulas in combination with serotonin for the correction of nutritional status disorders and gastrointestinal insufficiency in the postoperative period in oncological patients: results of a pilot study
Objective. To improve perioperative outcomes in patients with malignant GIT tumors and pre-existing NI through early use of a semi-elemental therapeutic formula in combination with continuous infusion of serotonin adipinate. Material and methods. This was a prospective, randomized, single-center pilot study including 44 patients aged >65 years after elective GIT surgery for malignant neoplasms with documented NI (≥2 points on NRS-2002) and GII (≥3 points on the LIFE scale). All patients received a low-rate intravenous infusion of serotonin adipinate (20 mg/day) until resolution of GII. Early enteral nutritional support was initiated simultaneously: in the main group, a semi-elemental whey protein hydrolysate-based formula (Peptamen Intense) was used; in the control group, a standard polymeric formula (Nutricomp Intensive) was administered. The severity of GII was assessed using the LIFE scale; plasma serotonin levels, amino acid profile (methionine, arginine, valine, citrulline, etc.), laboratory markers of nutritional status and their dynamics were evaluated on postoperative days 1, 2, and 5. Results. In both groups, serotonin supplementation led to a rapid normalization of initially reduced plasma serotonin levels (from 49.8 ng/mL [19; 71.2] to values within the reference range already by postoperative day 1, with subsequent stabilization). In the main group, the semi-elemental formula provided a more pronounced nutritional effect: by day 5 there was a significant restoration (p<0.05) of initially decreased methionine, arginine, and valine concentrations compared with the control group. A less pronounced catabolic trend was observed for citrulline, a marker of functional enterocyte mass, along with a more favorable course of GII according to the LIFE scale (p<0.05) in the main group. Significant negative correlations were identified between GII severity and arginine levels (r=–0.994; 95% CI [–0.9968; –0.9890], p=0.01) and citrulline levels (r=–0.614; 95% CI [–0.819; –0.271], p=0.04), indicating active utilization of these amino acids in reparative processes under combined therapy. Conclusion. The results of this pilot study demonstrate the potential of early use of a semi-elemental enteral formula on the background of prokinetic therapy with serotonin adipinate to optimize postoperative restoration of GIT function and correction of malnutrition in oncologic patients with pre-existing NI and GII. The data obtained indicate a more favorable dynamics of the amino acid profile (methionine, arginine, valine, citrulline) and a trend toward less severe GII on the LIFE scale compared with a standard polymeric formula. However, given the small sample size and short follow-up period, these findings require confirmation in larger multicenter studies.
- 8 April 2026
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (2) , 75-85
L-Arginine as a New Tool in the Intensive Care of Cardiovascular Disorders: Review
Relevance. Cardiovascular diseases (CVDs) remain one of the leading causes of mortality worldwide. In recent years, significant attention has been given to L-arginine, a conditionally essential amino acid that serves as a key precursor of nitric oxide, a critically important mediator of vascular function. Dysregulation of L-arginine metabolism and the development of endothelial dysfunction play a significant pathogenetic role in the development and progression of CVDs. Objective. This review aims to systematize current data on the role of L-arginine in the regulation of vascular tone, its impact on endothelium-dependent vasodilation, and to assess the potential application of L-arginine in the intensive care of cardiovascular diseases. Material and methods. A comprehensive analysis of the results of in vitro and in vivo experimental studies, as well as clinical trials focused on examining the influence of L-arginine on endothelial function, hemodynamic parameters, coronary blood flow, and other cardiovascular system parameters was conducted. Particular attention was given to analyzing the molecular mechanisms of NO-mediated action of L-arginine and its interaction with the arginase enzyme. Results. L-arginine contributes to enhancing endothelium-dependent vasodilation, reducing blood pressure, and can have a positive impact in cases of coronary heart disease, heart failure, and atherosclerosis. It is important to note that the effectiveness of L-arginine therapy can be modulated by the level of ADMA, an endogenous inhibitor of nitric oxide synthase (NOS). Conclusion. L-arginine represents a promising therapeutic agent for use in the intensive care of CVDs, especially in patients facing potential ischemia-reperfusion syndrome. To determine optimal therapeutic strategies, including dosage selection and identification of target patient groups, further large-scale, placebo-controlled clinical studies are necessary.
- 8 April 2026
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (2) , 75-85
L-Arginine as a New Tool in the Intensive Care of Cardiovascular Disorders: Review
Relevance. Cardiovascular diseases (CVDs) remain one of the leading causes of mortality worldwide. In recent years, significant attention has been given to L-arginine, a conditionally essential amino acid that serves as a key precursor of nitric oxide, a critically important mediator of vascular function. Dysregulation of L-arginine metabolism and the development of endothelial dysfunction play a significant pathogenetic role in the development and progression of CVDs. Objective. This review aims to systematize current data on the role of L-arginine in the regulation of vascular tone, its impact on endothelium-dependent vasodilation, and to assess the potential application of L-arginine in the intensive care of cardiovascular diseases. Material and methods. A comprehensive analysis of the results of in vitro and in vivo experimental studies, as well as clinical trials focused on examining the influence of L-arginine on endothelial function, hemodynamic parameters, coronary blood flow, and other cardiovascular system parameters was conducted. Particular attention was given to analyzing the molecular mechanisms of NO-mediated action of L-arginine and its interaction with the arginase enzyme. Results. L-arginine contributes to enhancing endothelium-dependent vasodilation, reducing blood pressure, and can have a positive impact in cases of coronary heart disease, heart failure, and atherosclerosis. It is important to note that the effectiveness of L-arginine therapy can be modulated by the level of ADMA, an endogenous inhibitor of nitric oxide synthase (NOS). Conclusion. L-arginine represents a promising therapeutic agent for use in the intensive care of CVDs, especially in patients facing potential ischemia-reperfusion syndrome. To determine optimal therapeutic strategies, including dosage selection and identification of target patient groups, further large-scale, placebo-controlled clinical studies are necessary.
- 31 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 6,p. 107-117
Gastrointestinal failure in postoperative period
The review is devoted to postoperative gastrointestinal insufficiency, diagnosis and modern therapeutic approaches. Special attention is paid to the most vulnerable groups of patients, as well as to clinical variants of this pathological process. Modern therapeutic strategies are highlighted taking into account the most significant pathogenetic mechanisms. The key areas for perspective research are outlined.
- 31 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 6,p. 107-117
Gastrointestinal failure in postoperative period
The review is devoted to postoperative gastrointestinal insufficiency, diagnosis and modern therapeutic approaches. Special attention is paid to the most vulnerable groups of patients, as well as to clinical variants of this pathological process. Modern therapeutic strategies are highlighted taking into account the most significant pathogenetic mechanisms. The key areas for perspective research are outlined.
- 10 December 2025
- Published by ECO-Vector LLC (Publications) in Regional Anesthesia and Acute Pain Management
- Vol. 19 (4) , 333-344
Effect of nonsteroidal anti-inflammatory drug selection for preventive analgesia on the severity of postoperative cognitive dysfunction: a prospective, comparative study
BACKGROUND: Postoperative cognitive dysfunction is a common complication, with neuroinflammation recognized as one of its key pathogenetic mechanisms. Despite extensive evidence supporting the use of nonsteroidal anti-inflammatory drugs for preventive analgesia, comparative studies evaluating their effects on blood–brain barrier injury markers and cognitive outcomes remain limited and do not allow for definitive conclusions. AIM: This study aimed to compare the effects of preventive administration of ibuprofen and ketoprofen on the level of neuroinflammation and the severity of early postoperative cognitive dysfunction in patients undergoing elective surgery under general anesthesia. METHODS: A single-center, randomized, prospective study was conducted. A total of 45 patients were enrolled and randomly assigned into two groups. Thirty minutes before anesthesia induction, patients in group 1 (n = 23) received intravenous ibuprofen 800 mg, whereas patients in group 2 (n = 22) received intravenous ketoprofen 100 mg. Biochemical markers (S100B, C-reactive protein, fibrinogen, and D-dimer) and cognitive test results (MoCA, TMT, MMSE) were assessed over time. RESULTS: The groups were comparable in baseline characteristics. On postoperative day 1, S100B concentration in the ibuprofen group was significantly lower than in the ketoprofen group: 0.117 ng/mL vs. 0.164 ng/mL, respectively (p = 0.046). By postoperative day 3, this difference was no longer observed. No statistically significant intergroup differences were found in the trends of cognitive test results or in the levels of C-reactive protein, fibrinogen, and D-dimer. None of the patients demonstrated cognitive impairment meeting the predefined criterion (deviation ≥ 2 points on cognitive tests). CONCLUSION: Preventive administration of ibuprofen was associated with a less pronounced increase in S100B levels in the early postoperative period compared with ketoprofen, which may indicate a stronger inhibitory effect on neuroinflammation. However, this difference resulted only in a statistically non-significant reduction in the incidence of postoperative cognitive dysfunction. The main limitations of the study include the small sample size and the short duration of postoperative cognitive follow-up.
- 10 December 2025
- Published by ECO-Vector LLC (Publications) in Regional Anesthesia and Acute Pain Management
- Vol. 19 (4) , 333-344
Effect of nonsteroidal anti-inflammatory drug selection for preventive analgesia on the severity of postoperative cognitive dysfunction: a prospective, comparative study
BACKGROUND: Postoperative cognitive dysfunction is a common complication, with neuroinflammation recognized as one of its key pathogenetic mechanisms. Despite extensive evidence supporting the use of nonsteroidal anti-inflammatory drugs for preventive analgesia, comparative studies evaluating their effects on blood–brain barrier injury markers and cognitive outcomes remain limited and do not allow for definitive conclusions. AIM: This study aimed to compare the effects of preventive administration of ibuprofen and ketoprofen on the level of neuroinflammation and the severity of early postoperative cognitive dysfunction in patients undergoing elective surgery under general anesthesia. METHODS: A single-center, randomized, prospective study was conducted. A total of 45 patients were enrolled and randomly assigned into two groups. Thirty minutes before anesthesia induction, patients in group 1 (n = 23) received intravenous ibuprofen 800 mg, whereas patients in group 2 (n = 22) received intravenous ketoprofen 100 mg. Biochemical markers (S100B, C-reactive protein, fibrinogen, and D-dimer) and cognitive test results (MoCA, TMT, MMSE) were assessed over time. RESULTS: The groups were comparable in baseline characteristics. On postoperative day 1, S100B concentration in the ibuprofen group was significantly lower than in the ketoprofen group: 0.117 ng/mL vs. 0.164 ng/mL, respectively (p = 0.046). By postoperative day 3, this difference was no longer observed. No statistically significant intergroup differences were found in the trends of cognitive test results or in the levels of C-reactive protein, fibrinogen, and D-dimer. None of the patients demonstrated cognitive impairment meeting the predefined criterion (deviation ≥ 2 points on cognitive tests). CONCLUSION: Preventive administration of ibuprofen was associated with a less pronounced increase in S100B levels in the early postoperative period compared with ketoprofen, which may indicate a stronger inhibitory effect on neuroinflammation. However, this difference resulted only in a statistically non-significant reduction in the incidence of postoperative cognitive dysfunction. The main limitations of the study include the small sample size and the short duration of postoperative cognitive follow-up.
- 22 October 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 5,p. 88-97
Analytical review of the pathophysiological mechanisms of ischemia-reperfusion syndrome development in PCI
Introduction. Despite the known risks of myocardial damage as a result of reperfusion, current treatment strategies often focus only on immediate recanalization of the coronary arteries. At the same time, a lot of experimental and clinical data confirms that this procedure can provoke additional ischemic reperfusion injury to the myocardium. Objective. Analysis of the existing literature on ischemia-reperfusion syndrome in percutaneous coronary intervention in order to systematize knowledge about the mechanisms of its development. Material and methods. The study was conducted in collaboration with international organizations to analyze PRISMA (Preferred Reporting Articles for Systematic Reviews and Meta-analyses). The search for users was conducted in the PubMed, Google Scholar, and eLibrary.ru. Results. A total of 4.268 initial results were found, including PubMed — 2.134 publications, Google Scholar — 1.280 and eLibrary.ru — 854 publication. Only 1.523 papers turned out to be relevant, after studying which only 70 full-text publications were selected for the review, which met all the selection criteria and were included in the analysis. Most studies describe the pathophysiological mechanisms contributing to the development of ischemia-reperfusion syndrome during percutaneous coronary intervention. Conclusion. Ischemia-reperfusion syndrome causes activation of various pathophysiological mechanisms, among which endothelial dysfunction, oxidative stress, inflammatory response, and energy exchange disorders play a leading role. This is the basis for the development of new therapeutic strategies to prevent myocardial damage during percutaneous coronary interventions and improve treatment outcomes in patients with coronary artery disease.
- 22 October 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 5,p. 88-97
Analytical review of the pathophysiological mechanisms of ischemia-reperfusion syndrome development in PCI
Introduction. Despite the known risks of myocardial damage as a result of reperfusion, current treatment strategies often focus only on immediate recanalization of the coronary arteries. At the same time, a lot of experimental and clinical data confirms that this procedure can provoke additional ischemic reperfusion injury to the myocardium. Objective. Analysis of the existing literature on ischemia-reperfusion syndrome in percutaneous coronary intervention in order to systematize knowledge about the mechanisms of its development. Material and methods. The study was conducted in collaboration with international organizations to analyze PRISMA (Preferred Reporting Articles for Systematic Reviews and Meta-analyses). The search for users was conducted in the PubMed, Google Scholar, and eLibrary.ru. Results. A total of 4.268 initial results were found, including PubMed — 2.134 publications, Google Scholar — 1.280 and eLibrary.ru — 854 publication. Only 1.523 papers turned out to be relevant, after studying which only 70 full-text publications were selected for the review, which met all the selection criteria and were included in the analysis. Most studies describe the pathophysiological mechanisms contributing to the development of ischemia-reperfusion syndrome during percutaneous coronary intervention. Conclusion. Ischemia-reperfusion syndrome causes activation of various pathophysiological mechanisms, among which endothelial dysfunction, oxidative stress, inflammatory response, and energy exchange disorders play a leading role. This is the basis for the development of new therapeutic strategies to prevent myocardial damage during percutaneous coronary interventions and improve treatment outcomes in patients with coronary artery disease.
- Open Access
- 17 August 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (6) , 487-493
Potential for infusion correction of COVID-19-associated endotheliopathy
Aim. To evaluate the relationship between the systemic inflammatory response and the severity of COVID-19-associated endotheliopathy and the effect of succinate-containing crystalloid solution (sodium meglumine succinate) on it in patients with severe COVID-19. Materials and methods. Clinical and laboratory parameters of 53 intensive care unit's patients with COVID-19 complicated by community-acquired bilateral multisegmental pneumonia were analyzed. Intensive therapy complex of 27 patients (study group) included daily infusion of 1.5% solution of sodium meglumine succinate (Reamberin) in the daily dose of 10 ml/kg for at least 11 days (or during the whole stay in the unit). A similar volume of Ringer's solution was present in the control group of 26 patients. The levels of endotheliocytosis, homocysteine, and systemic inflammatory response were determined at all stages of the study. Results. The evaluation of endotheliopathy degree in the meglumine succinate group showed a significant reduction of initially elevated levels of endotheliemia and homocysteinemia at all study stages. The pattern of changes in the study group was highly correlated (r=0.900.96) with the dynamics of systemic inflammatory response parameters-fibrinogenemia, C-reactive protein and interleukin-6 levels. As normalization of the immune imbalance, we regarded the termination of lymphopenia in the Reamberin group. Conclusion. Early inclusion of Reamberin infusion into intensive therapy of severe COVID-19, in comparison with Ringer's solution, leads to significant and stable correction of the severity of systemic inflammatory response, which in turn is naturally reflected in the severity of endothelial dysfunction, multiple organ failure, and also leads to a decrease in 28-day mortality.
- 17 August 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (6) , 487-493
Open AccessPotential for infusion correction of COVID-19-associated endotheliopathy
Aim. To evaluate the relationship between the systemic inflammatory response and the severity of COVID-19-associated endotheliopathy and the effect of succinate-containing crystalloid solution (sodium meglumine succinate) on it in patients with severe COVID-19. Materials and methods. Clinical and laboratory parameters of 53 intensive care unit's patients with COVID-19 complicated by community-acquired bilateral multisegmental pneumonia were analyzed. Intensive therapy complex of 27 patients (study group) included daily infusion of 1.5% solution of sodium meglumine succinate (Reamberin) in the daily dose of 10 ml/kg for at least 11 days (or during the whole stay in the unit). A similar volume of Ringer's solution was present in the control group of 26 patients. The levels of endotheliocytosis, homocysteine, and systemic inflammatory response were determined at all stages of the study. Results. The evaluation of endotheliopathy degree in the meglumine succinate group showed a significant reduction of initially elevated levels of endotheliemia and homocysteinemia at all study stages. The pattern of changes in the study group was highly correlated (r=0.900.96) with the dynamics of systemic inflammatory response parameters-fibrinogenemia, C-reactive protein and interleukin-6 levels. As normalization of the immune imbalance, we regarded the termination of lymphopenia in the Reamberin group. Conclusion. Early inclusion of Reamberin infusion into intensive therapy of severe COVID-19, in comparison with Ringer's solution, leads to significant and stable correction of the severity of systemic inflammatory response, which in turn is naturally reflected in the severity of endothelial dysfunction, multiple organ failure, and also leads to a decrease in 28-day mortality.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 6,p. 83
Endothelial injury in severe COVID-19 as a reason for infusion therapy choice
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) на выраженность эндотелиальной дисфункции у пациентов с тяжелой формой новой коронавирусной инфекции (COVID-19). МАТЕРИАЛ И МЕТОДЫ В исследование включены 53 пациента с тяжелой формой COVID-19, осложненной двусторонней полисегментарной пневмонией. Все пациенты исходно методом конвертов рандомизированы на две группы. В комплекс терапии пациентов группы исследования (n=27) включена ежедневная инфузия сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) — препарата реамберин в дозе 10 мл на 1 кг массы тела в течение 4 ч однократно с курсом до 11 дней (или на протяжении времени пребывания в отделении реанимации). Пациенты контрольной группы (n=26) получали в качестве инфузионной среды раствор Рингера в том же объеме. В динамике исследовали содержание эндотелиоцитов, гомоцистеина, тромбоцитов и показатели коагулограммы. РЕЗУЛЬТАТЫ И ОБСУЖДЕНИЕ Оценка выраженности эндотелиальной дисфункции показала, что у пациентов, получавших реамберин, определялось более выраженное (p<0,05) снижение исходно повышенного уровня эндотелиоцитов и концентрации гомоцистеина на всех этапах исследования. Существенные межгрупповые различия проявлялись начиная со вторых суток наблюдения. Инфузионная коррекция выраженности эндотелиальной дисфункции приводила к снижению частоты тромботических осложнений, вероятности перевода на инвазивную искусственную вентиляцию легких и летальности по сравнению с традиционным подходом. ЗАКЛЮЧЕНИЕ Применение сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) в комплексной терапии тяжелых форм новой коронавирусной инфекции оправдано более значительной и стойкой коррекцией исходно выраженной дисфункции эндотелия, способствующей снижению количества тромботических осложнений, переводов на инвазивную искусственную вентиляцию легких и летальности.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 6,p. 83
Endothelial injury in severe COVID-19 as a reason for infusion therapy choice
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) на выраженность эндотелиальной дисфункции у пациентов с тяжелой формой новой коронавирусной инфекции (COVID-19). МАТЕРИАЛ И МЕТОДЫ В исследование включены 53 пациента с тяжелой формой COVID-19, осложненной двусторонней полисегментарной пневмонией. Все пациенты исходно методом конвертов рандомизированы на две группы. В комплекс терапии пациентов группы исследования (n=27) включена ежедневная инфузия сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) — препарата реамберин в дозе 10 мл на 1 кг массы тела в течение 4 ч однократно с курсом до 11 дней (или на протяжении времени пребывания в отделении реанимации). Пациенты контрольной группы (n=26) получали в качестве инфузионной среды раствор Рингера в том же объеме. В динамике исследовали содержание эндотелиоцитов, гомоцистеина, тромбоцитов и показатели коагулограммы. РЕЗУЛЬТАТЫ И ОБСУЖДЕНИЕ Оценка выраженности эндотелиальной дисфункции показала, что у пациентов, получавших реамберин, определялось более выраженное (p<0,05) снижение исходно повышенного уровня эндотелиоцитов и концентрации гомоцистеина на всех этапах исследования. Существенные межгрупповые различия проявлялись начиная со вторых суток наблюдения. Инфузионная коррекция выраженности эндотелиальной дисфункции приводила к снижению частоты тромботических осложнений, вероятности перевода на инвазивную искусственную вентиляцию легких и летальности по сравнению с традиционным подходом. ЗАКЛЮЧЕНИЕ Применение сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) в комплексной терапии тяжелых форм новой коронавирусной инфекции оправдано более значительной и стойкой коррекцией исходно выраженной дисфункции эндотелия, способствующей снижению количества тромботических осложнений, переводов на инвазивную искусственную вентиляцию легких и летальности.